Global Adipose Derived Stem Cell Therapy Market: Share, Size, Growth, Opportunities, and Forecast 2022-2028

 

Adipose-derived stem cells (ADSCs) are progenitors of a wide range of cell types that can be differentiated from adipocytes. Due to their similar multipotency to mesenchymal stem cells found in bone marrow, ADSCs can serve as a substitute for bone marrow as a source of stem cells. Adipose stem cells (ASCs) from adipose tissue are separated using a variety of manual and automatic stem cell separation techniques. Additionally, flow cytometry can distinguish ADSCs from other stem cells in a cell solution.

The important benefit is that fat tissues contain between 100 and 1000 times as many mesenchymal stem cells as bone marrow does. Additionally, the procedure for obtaining these stem cells from adipose tissue is less invasive and simpler than collecting bone marrow.

Mesenchymal stem cells known as Adipose Derived Stem Cell Therapy Market are taken from adult fat tissues during procedures like abdominoplasty, liposuction, or breast reduction. The ability to differentiate into a variety of cell lineages, including chondrocytes, adipocytes, and others, is possessed by Adipose Derived Stem Cell Therapy Market. This characteristic allows these multipotent stem cells to take the place of bone marrow as a rich source of stem cells.

Currently, a wide range of applications including regenerative medicine, tissue engineering, cell therapy, and stem cell differentiation studies make use of adipose tissue-derived stem cells. In comparison to other stem cells, ADSCs have a much greater potential for regenerative medicine. This is a result of, among other things, its anti-inflammatory, immunomodulatory, anti-scarring, and anti-apoptotic properties.

Adipose-Derived Stem Cell Therapy Market includes the widespread use of ADSCs in regenerative medicine and the rising public awareness of the field's significance in treating target and rare diseases. ADSCs are currently used in stem cell therapy for a variety of purposes, including fat reconstruction, myocardial and cardiovascular regeneration, and bone regeneration. Their use in treating diabetes is just one of the many diverse ways that biomedical sciences and medicine have applied them.

The development of advanced manufacturing processes for stem cell lines is being fueled by a number of factors, including increasing funding and investment in stem cell research, expanding regulatory approvals for international clinical trials of ADSCs, and expanding strategic alliances between well-known businesses and academic institutions.

Key Players

BioRestorative Therapies, Inc., Celltex Therapeutics Corporation, Antria, Inc., Cytori Therapeutics Inc., Intrexon Corporation, Mesoblast Ltd., iXCells Biotechnologies, Pluristem Therapeutics, Inc., Thermo Fisher Scientific, Inc., Tissue Genesis, Inc., Cyagen US Inc., Celprogen, Inc.,